Sarah A. Reda

https://documentapi-fargate-documentbucket-15qi4tpdvnhlz.s3.amazonaws.com/218/d2a5b100-504e-11ef-931e-8373c6b518fb.jpg

First Name

Sarah

Last Name

Reda

NPI

1003304510

Faculty ID

17794

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Female

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

CHAM Provider

Off

Professional Title

Elsevier Profile

EMR ID

186405

Visit Type ID

2499

Is Open Scheduling

On

Daisy Berisha

https://assets.montefioreeinstein.org/profiles/images/physphoto/Berisha_Daisy_MD_420x504.jpg

First Name

Daisy

Last Name

Berisha

NPI

1124682752

Faculty ID

16649

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Female

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Clinical Focus

Clinical focus in primary eye care and ocular disease including diabetic eye examinations, glaucoma screenings and treatments, anterior segment disease as well as pediatric eye examinations for children aged 5 and up.<quillbot-extension-portal></quillbot-extension-portal>

Research Focus

Dr. Berisha takes a special interest in dry eye disease, screening and management of glaucoma and diabetic eye disease, and finding the ideal corrective eyewear for each patient.<quillbot-extension-portal></quillbot-extension-portal>

EMR ID

138199

Is Open Scheduling

Off

Sriram Machineni

https://documentapi-fargate-documentbucket-15qi4tpdvnhlz.s3.amazonaws.com/218/c68653a0-bec9-11ee-aa99-759018b444d6.jpg

First Name

Sriram

Last Name

Machineni

NPI

1750350666

Faculty ID

17510

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Male

Provider Type

Primary Care

Email

Phone

Titles

Locations

Education and Trainings

Professional Interests

<p class="MsoNormal" style="margin: 0in; font-size: 12pt; font-family: Calibri, sans-serif;">Dr. Machineni obtained his medical degree from the All India Institute of Medical Sciences in New Delhi, followed by a residency in internal medicine at the State University of New York at &nbsp;Buffalo. He served as chief resident and primary care teaching physician at Buffalo General Hospital. He subsequently completed a clinical and research fellowship in obesity medicine and metabolism at Massachusetts General Hospital/ Harvard Medical School and stayed on as an instructor. Dr. Machineni studied energy balance and body fat regulation in animal models allowing the interpretation of clinical research findings and phenotypes in the context of physiology.&nbsp;</p>
<p class="MsoNormal" style="margin: 0in; font-size: 12pt; font-family: Calibri, sans-serif;">&nbsp;</p>
<p class="MsoNormal" style="margin: 0in; font-size: 12pt; font-family: Calibri, sans-serif;">Dr. Machineni moved to the University of North Carolina at Chapel Hill (UNC) to start a clinical obesity program for treatment, education, and pharmaceutical clinical obesity trials. During his term at UNC, he helped create an obesity primary care network in central North Carolina. He was recruited to Montefiore Medical Center to develop a new medical obesity program.</p>
<p style="margin-right: 0in; margin-left: 0in; font-size: 12pt; font-family: 'Times New Roman', serif; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;"><span style="font-family: Calibri, sans-serif;">The Fleischer Institute Medical Weight Center at Montefiore Einstein, founded by Dr. Machineni, is designed to support clinical, educational, and research endeavors in the field of obesity medicine. The program leverages individual variations in response to treatments and uses multiple modalities for weight reduction to treat the comorbidities of obesity and improve quality of life. Special programs are available for individuals who need to lose weight to quality for medical and surgical procedures. The Medical Weight Center works closely with the Montefiore bariatric surgery program to offer a broad spectrum of treatment modalities.</span></p>
<p style="margin-right: 0in; margin-left: 0in; font-size: 12pt; font-family: 'Times New Roman', serif; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;"><span style="font-family: Calibri, sans-serif;">Dr. Machineni has clinical expertise in the m</span><span style="font-family: Calibri, sans-serif; font-size: 12pt;">ultidisciplinary management of obesity, anti-obesity medications, and post-bariatric medical complications, including nutritional deficiencies, hypoglycemia, weight regain, malabsorption, and diarrhea. He</span><span style="font-family: Calibri, sans-serif;">&nbsp;is among a handful of physicians in the New York area with Castle Connolly Top Doctors designation in obesity medicine.</span></p>
<p style="margin-right: 0in; margin-left: 0in; font-size: 12pt; font-family: 'Times New Roman', serif; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;">&nbsp;</p>

Research Areas

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Elsevier Profile

Selected Publications

<p>1: Garvey WT, Frias JP, Jastreboff AM, le Roux CW, Sattar N, Aizenberg D, Mao H,Zhang S, Ahmad NN, Bunck MC, Benabbad I, Zhang XM; <strong>SURMOUNT-2 investigators</strong>.Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2023 Jun 26:S0140-6736(23)01200-X. doi:10.1016/S0140-6736(23)01200-X. Epub ahead of print. PMID: 37385275.</p>
<p>2: Pagidipati NJ, Mulder H, Chiswell K, Lampron Z, Jones WS, <strong>Machineni S</strong>,Waitman LR, Mongraw-Chaffin M, Waterman F, Kumar N, Ramasamy A, Smolarz G,Peterson ED, O'Brien E. Evaluation of weight change and cardiometabolic risk factors in a real-world population of US adults with overweight or obesity. PrevMed. 2023 May;170:107496. doi:10.1016/j.ypmed.2023.107496. Epub 2023 Mar 29.PMID: 36997096.</p>
<p>3: Ro SJ, Lackey AR, Aymes SE, McCauley JL, Davis TC, Wang R, Stanley W, Ratner SP, <strong>Machineni S</strong>, Fiscus LC. Impact of a Community-Based Weight Management Program in a North Carolina Health Care System. Fam Med. 2023 Mar;55(3):189-194.doi: 10.22454/FamMed.2023.603918. Epub 2023 Jan 31. PMID: 36888674.</p>
<p>4: Aronne LJ, Bramblette S, Ingelfinger JR, Jastreboff AM, <strong>Machineni S,</strong> Massie N, Rosen CJ. When Weight Impacts Health. N Engl J Med. 2023 Jan 12;388(2):e2. doi: 10.1056/NEJMp2215794. PMID: 36630621.</p>
<p>5: Aronne LJ, Bramblette S, Huett-Garcia A, Ingelfinger JR, Jastreboff AM, <strong>Machineni S</strong>, Massie N, Rosen CJ. Weight and Health - Pathophysiology and&nbsp;Therapies. N Engl J Med. 2022 Dec 15;387(24):e62. doi: 10.1056/NEJMp2214423. PMID: 36516089.</p>
<p>6: le Roux CW, Zhang S, Aronne LJ, Kushner RF, Chao AM, <strong>Machineni S</strong>, Dunn J, Chigutsa FB, Ahmad NN, Bunck MC. Tirzepatide for the treatment of obesity: Rationale and design of the SURMOUNT clinical development program. Obesity (Silver Spring). 2023 Jan;31(1):96-110. doi: 10.1002/oby.23612. Epub 2022 Dec 7. PMID: 36478180; PMCID: PMC10107501.</p>
<p>7: Bionic Pancreas Research Group; Russell SJ, Beck RW, Damiano ER, El-Khatib FH, Ruedy KJ, Balliro CA, Li Z, Calhoun P, Wadwa RP, Buckingham B, Zhou K,Daniels M, Raskin P, White PC, Lynch J, Pettus J, Hirsch IB, Goland R, Buse JB,Kruger D, Mauras N, Muir A, McGill JB, Cogen F, Weissberg-Benchell J, Sherwood JS, Castellanos LE, Hillard MA, Tuffaha M, Putman MS, Sands MY, Forlenza G, Slover R, Messer LH, Cobry E, Shah VN, Polsky S, Lal R, Ekhlaspour L, Hughes MS, Basina M, Hatipoglu B, Olansky L, Bhangoo A, Forghani N, Kashmiri H, Sutton F, Choudhary A, Penn J, Jafri R, Rayas M, Escaname E, Kerr C, Favela-Prezas R, Boeder S, Trikudanathan S, Williams KM, Leibel N, Kirkman MS, Bergamo K, Klein KR, Dostou JM, <strong>Machineni S</strong>, Young LA, Diner JC, Bhan A, Jones JK, Benson M, Bird K, Englert K, Permuy J, Cossen K, Felner E, Salam M, Silverstein JM, Adamson S, Cedeno A, Meighan S, Dauber A. Multicenter, Randomized Trial of a Bionic Pancreas in Type 1 Diabetes. N Engl J Med. 2022 Sep 29;387(13):1161-1172. doi: 10.1056/NEJMoa2205225. PMID: 36170500; PMCID: PMC10028490.</p>
<p>8: Perreault L, Davies M, Frias JP, Laursen PN, Lingvay I, <strong>Machineni S</strong>, Varbo A,Wilding JPH, Wallenstein SOR, le Roux CW. Changes in Glucose Metabolism andGlycemic Status With Once-Weekly Subcutaneous Semaglutide 2.4 mg AmongParticipants With Prediabetes in the STEP Program. Diabetes Care. 2022 Oct1;45(10):2396-2405. doi: 10.2337/dc21-1785. PMID: 35724304; PMCID: PMC9862484.</p>
<p>9: Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, Kiyosue A,Zhang S, Liu B, Bunck MC, Stefanski A; <strong>SURMOUNT-1 Investigators</strong>. TirzepatideOnce Weekly for the Treatment of Obesity. N Engl J Med. 2022 Jul21;387(3):205-216. doi: 10.1056/NEJMoa2206038. Epub 2022 Jun 4. PMID: 35658024.</p>
<p>10: Klein KR, Freeman JLR, Dunn I, Dvergsten C, Kirkman MS, Buse JB, Valcarce C;<strong>SimpliciT1 research group</strong>. The SimpliciT1 Study: A Randomized, Double-Blind, Placebo-Controlled Phase 1b/2 Adaptive Study of TTP399, a Hepatoselective Glucokinase Activator, for Adjunctive Treatment of Type 1 Diabetes. Diabetes Care. 2021 Apr;44(4):960-968. doi:10.2337/dc20-2684. Epub 2021 Feb 23. PMID:33622669; PMCID: PMC7985421.</p>
<p>11: Melanie Davies, Louise F&aelig;rch, Ole K Jeppesen, Arash Pakseresht, Sue D Pedersen, Leigh Perreault, Julio Rosenstock, Iichiro Shimomura, Adie Viljoen, Thomas A Wadden, Ildiko Lingvay; <strong>STEP 2 Study Group</strong>.&nbsp; Semaglutide 2&middot;4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021 Mar 13;397(10278):971-984. PMID: 33667417.</p>
<p>12: Rosman L, Armbruster T, Kyazimzade S, Tugaoen Z, Mazzella AJ, Deyo Z, Walker J, <strong>Machineni S,</strong> Gehi A. Effect of a virtual self-management intervention for atrial fibrillation during the outbreak of COVID-19. Pacing Clin Electrophysiol. 2021 Mar;44(3):451-461. doi: 10.1111/pace.14188. Epub 2021 Feb 17. PMID: 33565642; PMCID: PMC8014277.</p>
<p>13: Wadden TA, Bailey TS, Billings LK, Davies M, Frias JP, Koroleva A, Lingvay I, O'Neil PM, Rubino DM, Skovgaard D, Wallenstein SOR, Garvey WT; <strong>STEP 3 Investigators.</strong> Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial. JAMA. 2021 Feb 24. PMID: 33625476; PMCID: PMC7905697.</p>
<p>14: Jensen SM, Thompson RE, <strong>Machineni S,</strong> Overby DW, Farrell TM. Refractory Hypocalcemia Following Stomach Intestinal Pylorus-Sparing Bariatric Surgery and Thyroidectomy: Successful Management With Creation of a Proximal Roux-en-Y Gastric Bypass. Am Surg. 2021 Apr;87(4):576-580. doi: 10.1177/0003134820952427. Epub 2020 Oct 30. PMID: 33125276.</p>
<p>&nbsp;</p>
<p>15: Kushner RF, Batsis JA, Butsch WS, Davis N, Golden A, Halperin F, Kidambi S, <strong>Machineni S,</strong> Novick M, Port A, Rubino DM, Saunders KH, Shapiro Manning L, Soleymani T, Kahan S. Weight History in Clinical Practice: The State of the Science and Future Directions. Obesity (Silver Spring). 2020 Jan;28(1):9-17. doi: 10.1002/oby.22642. PMID: 31858735.</p>
<p>16: Kushner RF, Butsch WS, Kahan S, <strong>Machineni S,</strong> Cook S, Aronne LJ. Obesity Coverage on Medical Licensing Examinations in the United States. What Is Being Tested? Teach Learn Med. 2017 Apr-Jun;29(2):123-128. doi:10.1080/10401334.2016.1250641. Epub 2016 Dec 29. PMID: 28033472.</p>
<p>17: Carmody JS, Ahmad NN, <strong>Machineni S,</strong> Lajoie S, Kaplan LM. Weight Loss After RYGB Is Independent of and Complementary to Serotonin 2C Receptor Signaling in Male Mice. Endocrinology. 2015 Sep;156(9):3183-91. doi: 10.1210/en.2015-1226. Epub 2015 Jun 11. PMID: 26066076; PMCID: PMC4541621.</p>
<p>18: Liou AP, Paziuk M, Luevano JM Jr, <strong>Machineni S,</strong> Turnbaugh PJ, Kaplan LM. Conserved shifts in the gut microbiota due to gastric bypass reduce host weight and adiposity. Sci Transl Med. 2013 Mar 27;5(178):178ra41. doi:10.1126/scitranslmed.3005687. PMID: 23536013; PMCID: PMC3652229.</p>
<p>19: Bose M, Teixeira J, Olivan B, Bawa B, Arias S, <strong>Machineni S,</strong> Pi-Sunyer FX, Scherer PE, Laferr&egrave;re B. Weight loss and incretin responsiveness improve glucose control independently after gastric bypass surgery. J Diabetes. 2010 Mar;2(1):47-55. doi: 10.1111/j.1753-0407.2009.00064.x. PMID: 20676394; PMCID: PMC2910618.</p>
<p>20: Bose M, <strong>Machineni S,</strong> Oliv&aacute;n B, Teixeira J, McGinty JJ, Bawa B, Koshy N, Colarusso A, Laferr&egrave;re B. Superior appetite hormone profile after equivalent weight loss by gastric bypass compared to gastric banding. Obesity (Silver Spring). 2010 Jun;18(6):1085-91. doi: 10.1038/oby.2009.473. Epub 2010 Jan 7.PMID: 20057364; PMCID: PMC2877144.</p>

EMR ID

179058

Is Open Scheduling

Off

David M. Loeb

https://assets.montefioreeinstein.org/profiles/images/Loeb_David_MD_2x.jpg

First Name

David

Last Name

Loeb

NPI

1841236676

Faculty ID

15556

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Pediatric

Department

Gender

Male

Email

Phone

Titles

Locations

Education and Trainings

Professional Interests

<p>Dr. Loeb has an active translational research laboratory focused on understanding bone tumor metastasis.&nbsp; His laboratory developed a clinically relevant mouse model of sarcoma metastasis, and has used this model to perform preclinical testing of novel agents that can interfere with this process.&nbsp; More basic scientific studies in the lab involve exploring the role of the Wnt signaling pathway in Ewing sarcoma migration, invasion, and metastasis.&nbsp; Dr. Loeb is also studying the role of an enzyme called RNA helicase DDX3 in Ewing sarcoma biology, especially how this enzyme affects the repair of damaged DNA. More recently, the laboratory has developed an interest in targeting the metabolic reprogramming associated with metastasis as a way to prevent the outgrowth of distant metastases from disseminated tumor cells.</p>
<p>&nbsp;</p>
<p>Dr. Loeb is also actively involved in clinical research, including the development of radiopharmaceutical agents for the treatment of bone metastases and the development of a small molecule inhibitor of DDX3.&nbsp; He serves as the local PI for a clinical trial of reduced intensity haploidentical bone marrow transplantation for children with high risk solid tumors.&nbsp; Finally, as an offshoot of his laboratory work, Dr. Loeb is involved in the development of biomarkers of metastatic risk and of minimal residual disease in children, adolescents, and young adults with sarcomas.</p>

Research Areas

Specialties

Expert Tags

Areas of Expertise

Expert Summary

<p>Dr. Loeb is a leading pediatric oncologist and NIH-funded researcher. He has extensive expertise in sarcoma research and clinical care and is a bone marrow transplantation specialist. Dr. Loeb’s research spans the spectrum from basic and translational studies to clinical trials using novel therapies.</p>

Research Profile

Clinical Profile

CHAM Provider

On

Professional Title

Elsevier Profile

Selected Publications

<p>Dr. Loeb's PubMed bibliography can be found here: &nbsp;</p>
<p><a href="https://www.ncbi.nlm.nih.gov/sites/myncbi/1fiIspwqfwUE46/bibliography/5…;

EMR ID

6405

Biography

<p>David Loeb, MD, PhD, is Chief, Pediatric Hematology, Oncology and Cellular Therapy at Children&rsquo;s Hospital at Montefiore and Professor, Pediatrics and Professor, Developmental and Molecular Biology at Montefiore Einstein. His clinical work focuses on tumors of connective tissue, such as bone and muscle. He also has expertise in the care of children with other solid tumors. As a member of the bone marrow transplantation team, Dr. Loeb also cares for patients with acute leukemias and has expertise in the application of immunotherapy to childhood cancer.</p><p>Dr. Loeb earned his Bachelor of Arts in biology in 1987 at Johns Hopkins University. In 1993, he received his Doctor of Philosophy in Pathology and, in 1994, his Doctor of Medicine at Columbia University. In 1994, he also began an internship in Pediatrics at the Johns Hopkins University School of Medicine, followed by a residency in 1995 and a fellowship in Pediatric Hematology Oncology at the same institution.</p><p>Dr. Loeb has an active translational research laboratory focused on understanding bone tumor metastasis. His laboratory developed a clinically relevant mouse model of sarcoma metastasis and has used this model to perform preclinical testing of novel agents that can interfere with this process. One area of focus is the metabolic differences between cancer cells and normal cells, and between metastases and the primary tumor, with the intention of targeting these differences therapeutically. More basic scientific studies in the lab involve exploring the role of the Wnt signaling pathway in Ewing sarcoma and osteosarcoma migration, invasion and metastasis. Dr. Loeb also studies the role of an enzyme called RNA helicase DDX3 in Ewing sarcoma biology, especially how this enzyme affects the repair of damaged DNA.</p><p>Dr. Loeb is also actively involved in clinical research, including the development of radiopharmaceutical agents for the treatment of bone metastases and the development of a small molecule inhibitor of DDX3. He has also directed a clinical trial of reduced intensity haploidentical bone marrow transplantation for children with high risk solid tumors. Stemming from his laboratory work, Dr. Loeb is involved in the development of biomarkers of metastatic risk and of minimal residual disease in children, adolescents and young adults with sarcomas. Dr. Loeb&rsquo;s original research, based on his clinical and laboratory studies, has been published in multiple journals and books.</p><p>Dr. Loeb has been a recipient of many awards, including the Director&rsquo;s Teaching Award in Clinical Science from Sidney Kimmel Comprehensive Cancer Center in 2006, 2010 and 2015, and The Justin Straus Chordoma Research Award in 2009.</p>

Is Open Scheduling

Off

Rodney L. Wright

https://assets.montefioreeinstein.org/profiles/images/Wright_Rodney_MD_2x.jpg

First Name

Rodney

Last Name

Wright

NPI

1639259195

Faculty ID

7019

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Languages

Gender

Male

Email

Phone

Titles

Locations

Education and Trainings

Research Areas

Areas of Expertise

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Clinical Focus

Dr. Wright&rsquo;s clinical interests include HIV during pregnancy, infectious diseases, sexually transmitted infections, global women&rsquo;s health and maternal fetal medicine.

Research Focus

Following his clinical interests, Dr. Wright&rsquo;s research focuses on HIV during pregnancy, prevention of perinatal HIV transmission, cervical dysplasia, HPV and global women&rsquo;s health.

Elsevier Profile

PubMed.gov URL

EMR ID

4235

Biography

<p>Rodney L. Wright, MD, MSc, is Director, Obstetrics and Gynecology, Wakefield Campus at Montefiore and Professor of Obstetrics and Gynecology and Women&rsquo;s Health, Division of Maternal Fetal Medicine at our Albert Einstein College of Medicine. Dr. Wright&rsquo;s clinical interests include HIV during pregnancy, infectious diseases, sexually transmitted infections, global women&rsquo;s health and maternal fetal medicine.</p><p>After receiving his Bachelor of Arts in biology and psychology from Emory University, Dr. Wright went on to the University of Pennsylvania School of Medicine, earning his Doctor of Medicine. His post graduate training began at the University of California, Irvine, where he completed a four-year residency in obstetrics and gynecology. Several years later, Dr. Wright pursued a three-year fellowship in maternal fetal medicine at Montefiore-Einstein. After completing this, he continued his education at Einstein, earning his Master of Science in clinical research methods.</p><p>Following his clinical interests, Dr. Wright&rsquo;s research focuses on HIV during pregnancy, prevention of perinatal HIV transmission, cervical dysplasia, HPV and global women&rsquo;s health. He&rsquo;s shared his research and expertise through many peer-reviewed journals, abstracts and invited presentations. He currently serves on the US Department of Health and Human Services Panel on Treatment of Pregnant Women with HIV Infection and Prevention of Perinatal Transmission.</p><p>An active member within the community, Dr. Wright is a member of the New York State AIDS Advisory Council and the New York State Taskforce on Maternal Mortality. He was awarded the Bronx County Medical Society &ldquo;Peer to Peer&rdquo; Excellence in Medicine Award. Dr. Wright received the New York State Commissioner of Health Commissioner&rsquo;s Special Recognition Award in recognition of his work as co-chair of the New York State Perinatal HIV Guidelines Committee and service to the New York State Ending the Epidemic (AIDS) Task Force. Dr. Wright is board certified in both Maternal Fetal Medicine and Obstetrics and Gynecology and is a member of several professional organizations including the New York Obstetrical Society, the Society for Maternal-Fetal Medicine and the American College of Obstetricians and Gynecologists.</p>

Is Open Scheduling

Off

Diana S. Wolfe

https://documentapi-fargate-documentbucket-15qi4tpdvnhlz.s3.amazonaws.com/218/2dbd2620-c4a9-11eb-9a84-87080e863cf8.jpg

First Name

Diana

Last Name

Wolfe

NPI

1972755445

Faculty ID

13455

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Female

Email

Phone

Titles

Locations

Education and Trainings

Professional Interests

<p>Diana S Wolfe, MD MPH is an Associate Professor in the Department of Obstetrics &amp; Gynecology and Women&rsquo;s Health, Division of Maternal Fetal Medicine. &nbsp;She is Associate Program Director of the Maternal Fetal Medicine Fellowship Program. &nbsp;</p>
<p>She established the MFM Cardiology Joint Program in 2015&nbsp;in response to the rising contribution of cardiovascular conditions to pregnancy related morbidity and mortality.&nbsp;&nbsp;The aim was to establish a multidisciplinary program to optimize the care of high-risk pregnant patients with known or suspected cardiac disease, as there is a real potential for communication gaps when patients are seen separately in contrast with parallel visits by different specialists.&nbsp;&nbsp;Patients are at all stages of their reproductive lives including preconception, pregnancy and postpartum.&nbsp;&nbsp;She works closely with the department of Cardiology both in the outpatient and inpatient setting to establish delivery plans and continued care postpartum.&nbsp;&nbsp;</p>
<p>&nbsp;</p>
<p>In addition,&nbsp;Dr. Wolfe has worked in global health,&nbsp;her most recent work in Africa was in Butare (Huye), Rwanda, serving as MFM subspecialist in the Human Resources for Health (HRH) program, directed by the Clinton Health Access Initiative (CHAI) and the Ministry of Health (MOH) of Rwanda.&nbsp; Dr. Wolfe was the first MFM subspecialist from Einstein to commence HRH at CHUB, Butare, Rwanda.&nbsp;&nbsp;Her interest began&nbsp;locally when she volunteered as a bilingual pregnancy counselor in Escondido, California.&nbsp; She then started working in Africa in 1998 where she served as a Peace Corps Volunteer in Mali, West Africa.&nbsp; She was part of the national Maternal and Child Health Program.&nbsp; She worked as health educator in a remote village, Karangasso, located in the Sikasso region, with a birth assistant to develop health education for 7 local villages on subjects such as infant nutrition, prenatal care, family planning, and developing community health committees for each village. &nbsp;She also initiated a birth assistant training program with the head nurse of the nearest local health center that included training subjects such as management of postpartum hemorrhage, contraception, and first steps in obstetric emergencies.&nbsp;&nbsp;During medical school, Dr. Wolfe worked on &ldquo;the Assessment of the Knowledge of Women&rsquo;s Health,&rdquo; a project that initiated with the Bedoin community of Israel.&nbsp; She implemented the same pre and post-training test to the 7 Malian villages where she served in the Peace Corps as well as to several villages in the Peruvian Amazon.&nbsp;</p>
<p>&nbsp;</p>
<p>&nbsp;</p>

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Clinical Focus

Dr. Wolfe&rsquo;s clinical focus is on maternal and fetal medicine (MFM).

Elsevier Profile

PubMed.gov URL

Selected Publications

<ol>
<li>Wolfe DS, Hameed AB, Taub CC, Zaidi AN, Bortnick AE.&nbsp;<a href="https://www.ncbi.nlm.nih.gov/pubmed/30278179">Addressing maternal mortality: the pregnant cardiac patient.</a>&nbsp;&nbsp;Am J Obstet Gynecol. 2019 Feb;220(2):167.e1-167.e8. doi: 10.1016/j.ajog.2018.09.035. Epub 2018 Sep 29.</li>
<li>Sahasrabudhe N, Teigen N, Wolfe DS, Taub C.&nbsp;&nbsp;<a href="https://www.ncbi.nlm.nih.gov/pubmed/29581907">Pregnancy after Prosthetic Aortic Valve Replacement: How Do We Monitor Prosthetic Valvular Function during Pregnancy?</a>Case Rep Obstet Gynecol. 2018 Jan 17;2018:4935957. doi: 10.1155/2018/4935957. eCollection 2018.</li>
<li>Kim SY, Wolfe DS, Taub CC.&nbsp;&nbsp;<a href="https://www.ncbi.nlm.nih.gov/pubmed/29063738">Cardiovascular outcomes of pregnancy in Marfan's syndrome patients: A literature review.</a>&nbsp;&nbsp;Congenit Heart Dis. 2018 Mar;13(2):203-209. doi: 10.1111/chd.12546. Epub 2017 Oct 23. Review.</li>
<li>Wolfe DS, Williams SF, Ross MG, Beall MH, Apuzzio JJ.&nbsp;<a href="https://www.ncbi.nlm.nih.gov/pubmed/23943702">Does preeclampsia predict the risk of late postpartum eclampsia?</a>&nbsp;&nbsp;AJP Rep. 2013 May;3(1):13-6. doi: 10.1055/s-0032-1329127. Epub 2013 Jan 25.</li>
<li><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=Wolfe%20D%5BAuthor%5D&amp;cau… D</a>1,&nbsp;<a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=Gong%20M%5BAuthor%5D&amp;caut… M</a>,&nbsp;<a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=Han%20G%5BAuthor%5D&amp;cauth… G</a>,&nbsp;<a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=Magee%20TR%5BAuthor%5D&amp;ca… TR</a>,&nbsp;<a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=Ross%20MG%5BAuthor%5D&amp;cau… MG</a>,&nbsp;<a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=Desai%20M%5BAuthor%5D&amp;cau… M</a>.Nutrient&nbsp;sensor mediated&nbsp;programmed&nbsp;nonalcoholic&nbsp;fatty&nbsp;liver&nbsp;disease&nbsp;in&nbsp;low&nbsp;birthweight offspring.&nbsp;&nbsp;<a title="American journal of obstetrics and gynecology." href="https://www.ncbi.nlm.nih.gov/pubmed/?term=Nutrient+sensor-mediated+prog… J Obstet Gynecol.</a>&nbsp;2012 Oct;207(4):308.e1-6. doi: 10.1016/j.ajog.2012.07.033. Epub 2012 Jul 31.</li>
</ol>

EMR ID

5620

Biography

<p>Diana S. Wolfe, MD, MPH, FACOG is Attending Physician at Montefiore and Associate Professor of Obstetrics and Gynecology and Women&rsquo;s Health at our Albert Einstein College of Medicine. Dr. Wolfe&rsquo;s clinical focus is on maternal and fetal medicine (MFM). In 2015, she established the MFM-Cardiology Joint Program at Montefiore&mdash;a multidisciplinary program to reduce morbidity and prevent mortality in expecting mothers with cardiovascular disease by optimizing the care of high-risk pregnant patients.</p><p>From 1988 to 1993, Dr. Wolfe pursued her Bachelor of Science in biology through the University of California San Diego, participating in the Education Abroad Program with Universita di Bologna, Italy from 1990 through 1991. In 1996 she began studies at University of California, Berkeley focusing on maternal child health, earning her Master of Public Health in 1998. After two years serving in the health extension of the Child Health Survival Program with the Peace Corps in Mali, Dr. Wolfe pursued her Doctor of Medicine at Ben Gurion University, Israel, receiving her degree in 2004.</p><p>Building on her clinical focus, Dr. Wolfe&rsquo;s research investigates cardio-obstetrics, preconception health, maternal morbidity and contraception in high risk women. She has published her research in several reviewed journals, book chapters and review articles.</p><p>Dr. Wolfe is board certified and is a member of the American College of Obstetrics and Gynecology and the Society for Maternal Fetal Medicine. She is active in global health, most recently working in Butare (Huye), Rwanda, serving as MFM subspecialist in the Human Resources for Health program, directed by the Clinton Health Access Initiative and the Ministry of Health of Rwanda.</p>

Is Open Scheduling

Off

Samson Wiseman

https://assets.montefioreeinstein.org/profiles/images/physphoto/Wiseman_Samson_MD_420x504.jpg

First Name

Samson

Last Name

Wiseman

NPI

1588761316

Faculty ID

10181

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Languages

Gender

Male

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Elsevier Profile

EMR ID

4748

Is Open Scheduling

Off

Lisa J. Underland

https://assets.montefioreeinstein.org/profiles/images/Underland_Lisa_DO_2x.jpg

First Name

Lisa

Last Name

Underland

NPI

1598083974

Faculty ID

13753

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Pediatric

Department

Gender

Female

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

On

Professional Title

Elsevier Profile

EMR ID

57202

Is Open Scheduling

Off

Mark I. Travin

https://assets.montefioreeinstein.org/profiles/images/physphoto/Travin_Mark_MD_420x504.jpg

First Name

Mark

Last Name

Travin

NPI

1275637597

Faculty ID

3407

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Male

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Clinical Focus

Dr. Travin's&nbsp;<span style="color:#4d4d4d;font-family:Arial, Helvetica, source-code-pro, Menlo, Monaco, Consolas, 'Courier New', monospace;font-size:16px;background-color:#ffffff;">clinical focus is on cardiac stress testing, radionuclide myocardial (perfusion and metabolic) imaging, and quantitative blood flow.</span><quillbot-extension-portal></quillbot-extension-portal>

Research Focus

<span style="color:#4d4d4d;font-family:Arial, Helvetica, source-code-pro, Menlo, Monaco, Consolas, 'Courier New', monospace;font-size:16px;background-color:#ffffff;">Dr. Travin's research focus is on cardiac innervation radionuclide imaging with I-123 mIBG and analogous PET tracers, and quantitative blood flow assessment with myocardial perfusion PET.</span><quillbot-extension-portal></quillbot-extension-portal>

Elsevier Profile

EMR ID

4152

Biography

<p>Mark I. Travin, MD, FACC, MASNC, is Director of Cardiovascular Nuclear Medicine at Montefiore. He is also a Professor of Radiology and Medicine at our Albert Einstein College of Medicine. His clinical focus is on cardiac stress testing, radionuclide myocardial (perfusion and metabolic) imaging, and quantitative blood flow.</p><p>Dr. Travin earned his Bachelor of Science and Master of Science degrees in 1979 at Yale College, followed by his Doctor of Medicine degree in 1983 from the University of Pennsylvania School of Medicine. After graduating, he went on to complete both an internship and a residency in medicine at Lenox Hill Hospital. In 1986, Dr. Travin began a fellowship in cardiology at the Brown University Integrated Fellowship Program. After that, he went on to complete a clinical and research fellowship in medicine and cardiology, with emphasis in nuclear cardiology at Massachusetts General Hospital and Spaulding Rehabilitation Hospital. </p><p>Dr. Travin?s research focus is on cardiac innervation radionuclide imaging with I-123 mIBG and analogous PET tracers, and quantitative blood flow assessment with myocardial perfusion PET. He has a significant body of published research on cardiac imaging, and has received numerous awards and honors, including the Cardiology Program Director?s Training Award, and the American Society of Nuclear Cardiology 2015 Zaret-Beller Distinguished Journal of Nuclear Cardiology Service Award. </p>

Is Open Scheduling

Off

Kristine E. Torres-Lockhart

https://documentapi-fargate-documentbucket-15qi4tpdvnhlz.s3.amazonaws.com/218/0b28f080-c3c8-11eb-9ea2-7374238588d1.jpg

First Name

Kristine

Last Name

Torres-Lockhart

NPI

1023467115

Faculty ID

16568

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Female

Provider Type

Primary Care

Email

Phone

Titles

Locations

Education and Trainings

Professional Interests

<p class="MsoNormal" style="margin: 0in; font-size: medium; font-family: Calibri, sans-serif;">Kristine Torres-Lockhart, MD, FASAM is an Assistant Professor of Medicine in the Division of General Internal Medicine and Department of Psychiatry and Behavioral Sciences at Montefiore Medical Center and the Albert Einstein College of Medicine, as well as the founding director of the Addiction Consult Service at Montefiore's Weiler Hospital. She is Program Director of the Addiction Medicine Fellowship and Co-Director of the Addiction Medicine rotation for medical trainees. An addiction medicine and internal medicine physician, she leads the development and implementation of health system interventions to improve substance use disorder (SUD) care in acute care settings and transitions of care to post-acute and ambulatory care settings.</p>
<p class="MsoNormal" style="margin: 0in; font-size: medium; font-family: Calibri, sans-serif;"><br />Dr. Torres-Lockhart provides SUD treatment, HIV/AIDS care, hepatitis C treatment, and general internal medicine care at several sites across Montefiore Medical Center, including a community health care center. She also actively teaches and supervises medical students, residents, and fellows. She is double board certified in addiction medicine and internal medicine and credentialed as an HIV specialist by the American Academy of HIV Medicine.&nbsp;<br /><br />Dr. Torres-Lockhart completed her fellowship training in addiction medicine at Montefiore Medical Center. Prior to arriving at Montefiore, she completed her residency training in internal medicine and primary care at Brigham and Women&rsquo;s Hospital in Boston, MA, where she also served as primary care chief medicine resident at the West Roxbury and Jamaica Plain Veterans Affairs Medical Centers. She received her undergraduate degree from Dartmouth College and her medical degree from the Geisel School of Medicine at Dartmouth. She is the PI for a HRSA training grant and co-PI for an OASAS training grant to lead the development of educational opportunities in building the addiction medicine workforce. She currently serves on the Board of Directors for the New York Society of Addiction Medicine previously as Communication Chair and now as Secretary.&nbsp;</p>

Research Areas

Research Profile

CHAM Provider

Off

Professional Title

Elsevier Profile

Selected Publications

<p class="MsoNormal" style="margin: 0in; font-size: medium; font-family: Calibri, sans-serif;">Singh-Tan, S., <strong>Torres-Lockhart, K.</strong>, Jakubowski, A., Lu, T., Starrels, J., De Lima, P., Arnsten, J., Nahvi, S., Southern, W. (2023). Addiction Consult Service and Inpatient Outcomes Among Patients with Alcohol Use Disorder. &nbsp;/J Gen Intern Med/, 1-8. doi:10.1007/s11606-023-08202-7</p>
<p class="MsoNormal" style="margin: 0in; font-size: medium; font-family: Calibri, sans-serif;">&nbsp;</p>
<p class="MsoNormal" style="margin: 0in; font-size: medium; font-family: Calibri, sans-serif;">Jakukowski, A., Singh-Tan, S., <strong>Torres-Lockhart, K</strong>., Nahvi, S., Stein, M., Fox, A. D., &amp; Lu, T. (2023). Hospital-based clinicians lack knowledge and comfort in initiating medications for opioid use disorder: opportunities for training innovation. /Addict Sci Clin Pract, 18/(1), 31. doi:10.1186/s13722-023-00386-x</p>
<p class="MsoNormal" style="margin: 0in; font-size: medium; font-family: Calibri, sans-serif;">&nbsp;</p>
<p class="MsoNormal" style="margin: 0in; font-size: medium; font-family: Calibri, sans-serif;">Calcaterra, S. L., Bottner, R., Martin, M., Englander, H., Weinstein, Z. M., Weimer, M. B., Lambert, E., Ronan, M., Huerta, S., Zaman, T., Ullal, M., Peterkin, A., <strong>Torres-Lockhart, K.</strong>, Buresh, M., O&rsquo;Brien, M., Synder, H., Herzig, S. J. (2022). Management of opioid use disorder, opioid withdrawal, and opioid overdose prevention in hospitalized adults: A systematic review of existing guidelines. /J Hosp Med, 17(9),/679-692/./doi:10.1002/jhm.12908</p>
<p class="MsoNormal" style="margin: 0in; font-size: medium; font-family: Calibri, sans-serif;">&nbsp;</p>
<p class="MsoNormal" style="margin: 0in; font-size: medium; font-family: Calibri, sans-serif;"><strong>Torres-Lockhart, K.</strong> E., Lu, T. Y., Weimer, M. B., Stein, M. R., &amp; Cunningham, C. O. (2022). Clinical Management of Opioid Withdrawal. /Addiction, 117/(9), 2540-2550. doi:10.1111/add.15818</p>
<p class="MsoNormal" style="margin: 0in; font-size: medium; font-family: Calibri, sans-serif;">&nbsp;</p>
<p class="MsoNormal" style="margin: 0in; font-size: medium; font-family: Calibri, sans-serif;">Cunningham, C. O., Khalid, L., Deng, Y., <strong>Torres-Lockhart, K.</strong>, Masyukova, M., Thomas, S., Zhang, C., Lu, T. (2022). A comparison of office-based buprenorphine treatment outcomes in Bronx community clinics before versus during the COVID-19 pandemic. /J Subst Abuse Treat, 135/, 108641. doi:10.1016/j.jsat.2021.108641</p>
<p class="MsoNormal" style="margin: 0in; font-size: medium; font-family: Calibri, sans-serif;">&nbsp;</p>
<p class="MsoNormal" style="margin: 0in; font-size: medium; font-family: Calibri, sans-serif;">Joseph, G., <strong>Torres-Lockhart, K.</strong>, Stein, M. R., Mund, P. A., &amp; Nahvi, S. (2021). Reimagining patient-centered care in opioid treatment programs: Lessons from the Bronx during COVID-19. /J Subst Abuse Treat, 122/, 108219. doi:10.1016/j.jsat.2020.108219</p>
<p class="MsoNormal" style="margin: 0in; font-size: medium; font-family: Calibri, sans-serif;">&nbsp;</p>
<p class="MsoNormal" style="margin: 0in; font-size: medium; font-family: Calibri, sans-serif;">He, L., <strong>Torres-Lockhart, K.</strong>, Forster, N., Ramakrishnan, S., Greninger, P., Garnett, M. J., McDermott, U., Rothenberg, S.M., Benes, C.H., Ellisen, L. W. (2013). Mcl-1 and FBW7 control a dominant survival pathway underlying HDAC and Bcl-2 inhibitor synergy in squamous cell carcinoma. /Cancer Discov, 3/(3), 324-337. doi:10.1158/2159-8290.CD-12-0417</p>
<p class="MsoNormal" style="margin: 0in; font-size: medium; font-family: Calibri, sans-serif;">&nbsp;</p>
<p class="MsoNormal" style="margin: 0in; font-size: medium; font-family: Calibri, sans-serif;">Ibrahim, Y. H., Garcia-Garcia, C., Serra, V., He, L., <strong>Torres-Lockhart, K</strong>., Prat, A., Anton, P., Cozar, P., Guzman, M., Grueso, J., Rodriguez, O., Calvo, M.T., Aura, C., Diez, O., Rubio, I.T., Perez, J., Rodon, J., Cortes, J., Ellisen, L.W., Scaltriti, M., Baselga, J. (2012). PI3K inhibition impairs BRCA1/2 expression and sensitizes BRCA-proficient triple-negative breast cancer to PARP inhibition. /Cancer Discov, 2/(11), 1036-1047. doi:10.1158/2159-8290.CD-11-0348</p>

EMR ID

113089

Biography

<p>Kristine E. Torres-Lockhart, MD, FASAM, is Director, Addiction Medicine Fellowship Program at Montefiore Einstein, Founding Director, Addiction Consult Service at Weiler Hospital and Assistant Professor, General Internal Medicine and Psychiatry and Behavioral Sciences at our Albert Einstein College of Medicine. Dr. Torres-Lockhart is a general internist, primary care provider and addiction medicine specialist. She focuses on caring for people who use substances and people with substance use disorders, providing care in hospital settings and in outpatient clinics.</p><p>After obtaining her Bachelor of Arts in neuroscience from Dartmouth College in 2010, Dr. Torres-Lockhart earned her Doctor of Medicine at the Geisel School of Medicine at Dartmouth in 2016. She completed an internship and residency in internal medicine and primary care at Brigham and Women&rsquo;s Hospital in 2019. Following this, Dr. Torres-Lockhart completed a fellowship in addiction medicine at Montefiore Einstein in 2020.</p><p>Dr. Torres-Lockhart's research focuses on evidence-based and harm-reduction-oriented strategies for addressing substance use disorder care in acute care settings, integration of addiction medicine into medical education and optimizing transitions of care for people who use drugs. She has been principal investigator and co-investigator on funded research projects and her work has been published in numerous peer-reviewed publications. Dr. Torres-Lockhart has also shared her work through numerous invited presentations, abstracts and poster presentations. She is a reviewer for scientific journals, including Addiction Science and Clinical Practice, the Journal of Addiction Medicine, the Journal of Substance Abuse Treatment and the Journal of Hospital Medicine.</p><p>Dr. Torres-Lockhart is board certified by the American Board of Internal Medicine and the American Board of Preventive Medicine with certification in Addiction Medicine. She is a Fellow of the American Society of Addiction Medicine, board member of the New York Society of Addiction Medicine and member of the Association for Multidisciplinary Education and Research in Substance Use and Addiction. In 2022, Dr. Torres-Lockhart received the President&rsquo;s Award at the New York Society of Addiction Medicine&rsquo;s Annual Conference. In 2023, she received the Quality Improvement Champion honor at the United Hospital Fund's Tribute to Excellence in Health Care and was a Rising Star Nominee for the Department of Medicine&rsquo;s Physician Recognition Awards at Montefiore Einstein.</p>

Is Open Scheduling

Off